Duke logo

TBCRC048 for Metastatic Breast Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug olaparib is safe and will work for men and women with metastatic breast cancer with a BRCA gene mutation.

What is the Condition Being Studied?

Metastatic Breast Cancer, BRCA gene mutation

Who Can Participate in the Study?

Adults who have:
- Stage IV metastatic breast cancer
- BRCA gene mutation (germline mutation or a somatic mutation)
--- If you have the mutation, you may not have progressed (gotten worse) on more than 2 chemotherapy regimens in the metastatic setting

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get the study drug olaparib during each 21 day treatment cycle
- Have tests, exams and procedures that are part of your standard of care and for study purposes.

Study Details

Full Title
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00100188
NCT:NCT03344965
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698